在人工智能（Artificial Intelligence, ...

Vertex Pharmaceuticals' late-stage pipeline. Vertex Pharmaceuticals' strategy is to develop medicines in areas with high ...

Given the rapidly evolving landscape of Artificial Intelligence, one of the biggest hurdles tech leaders often come across is ...

Over half of CEOs globally are experimenting with AI to generate text, images and other forms of data, a recent joint survey by Fortune and Deloitte found. Meanwhile, a third of organizations are ...

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) is reassessing its pain management program after disappointing FDA label discussions for Journavx. Phase II data for pain candidate VX-993 did not meet ...

Technically, Mark Sleeper doesn't know for sure he didn't get the placebo, but nothing in his 27 years of fighting the deadly lung disease cystic fibrosis has made him feel as good as the pill he ...

Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals ...

Vertex 股票已触及新的52周低点18.54美元，标志着该公司的重大下滑。根据 InvestingPro 数据，过去一年Vertex经历了急剧下跌，股价暴跌66.67%。仅在过去六个月内，该股已下跌45.5%，目前交易价格比其52周高点60.71美元低69%。这一下跌反映了持续的挑战和市场压力，这些因素严重影响了公司的表现，该公司在过去十二个月内未能实现盈利。当前的价格水平凸显了投资者的担忧， ...

Total revenues of $666.8 million for the full year 2024, representing a 16.5% year-over-year increase, indicating strong business growth. Cloud revenues grew by 28.6% year-over-year for the full year ...